BioNTech SE (BNTX) Cash & Equivalents (2018 - 2025)

BioNTech SE (BNTX) has 8 years of Cash & Equivalents data on file, last reported at $8.9 billion in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 14.35% year-over-year to $8.9 billion; the trailing twelve-month figure through Dec 2025 stood at $8.9 billion (down 14.35% YoY), and the FY2025 full-year result was $8.7 billion, down 16.87% from the prior year.
• Cash & Equivalents fell to $8.9 billion in Q4 2025, from $11.8 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $15.4 billion in Q2 2023 to a low of $432.8 million in Q3 2021.
• A 5-year average of $8.2 billion and a median of $10.5 billion in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents surged 1053.21% in 2023 and retreated 28.05% in 2024, its largest moves.
• Tracing BNTX's Cash & Equivalents over 5 years: stood at $1.9 billion in 2021, then surged by 631.05% to $14.2 billion in 2022, then fell by 11.35% to $12.5 billion in 2023, then declined by 16.88% to $10.4 billion in 2024, then decreased by 14.35% to $8.9 billion in 2025.
• Business Quant data shows BNTX's Cash & Equivalents at $8.9 billion in Q4 2025, $11.8 billion in Q3 2025, and $11.6 billion in Q2 2025.